1. GSK allies with Innovax for COVID-19 vaccine R&D project— Zentalis Pharma raises $165M in IPO — Drug discovery in the age of coronavirus — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Stannsoporfin R.I.P

Discussion in 'Mallinckrodt' started by anonymous, Nov 8, 2019 at 5:01 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    From the 10-Q but conveniently not announced on the investor call...
    "During the three months ended June 28, 2019, the Company recognized a full impairment on its in-process research and development ("IPR&D") asset related to stannsoporfin of $113.5 million as the Company will no longer pursue this development product."

    Great idea to spend $80 million on Infacare 2 years ago...great ROI...

    MNK business strategy...overpay and over borrow for assets no one else wants, destroy them in the marketplace or in the clinics, then take massive write downs in the future. Brilliant!

  2. anonymous

    anonymous Guest

    they have actually publicly announced this
  3. anonymous

    anonymous Guest

    ...I do not think they have publicly announced that they have failed miserably at completing trials that gain successful market approval...nor have they admitted that they over pay, over leverage debt to buy products no one else wants or will pay for, inflate earnings per share through manipulating their costs and to boost their bonuses...This team does not admit they are the laughing stock of the industry. However, thanks for monitoring the comments and trying to defend these fraudsters...
  4. anonymous

    anonymous Guest

    The original post was about the purchase. Which they addressed multiple times. The other stuff you brought up had nothing to do with the original post. You must be the guy they keep talking about with piss stains on his pants.
  5. anonymous

    anonymous Guest

    they just sold the rights to the name Sonorant to Hugh’s brother for 19 million. He will rent it back to use for 4 million a year once the company goes active however if we go bankrupt first his brother gets a bonus of 25 million.